Kidney cancer research program support services for congressionally directed medical research programs
Ended Awarded Last action
- Contract number
- HT942524F0064
- Awardee
-
Leidos, Inc. UEI QLNMVC12KWY3 Part of Leidos Holdings, Inc.
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $256,417
Award facts
- Opportunity
-
- Meeting, Programmatic, and Administrative Support Services Pre-Solicitation · W81XWH22R0025 · Posted Aug 16, 2021
- Contract value 70% obligated
- $364,347.19 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$107,931 | |
| Terminate for Convenience | $0 | |
| Original award | $364,347 |
About this award
Leidos, Inc. has been awarded a delivery order valued at $364,347.19 by the Defense Health Agency to provide kidney cancer research program support services for the Congressionally Directed Medical Research Programs (CDMRP). This Cost Plus Fixed Fee contract, with an ultimate completion date of July 29, 2025, will be performed in Frederick, Maryland. The award carries no set-aside designation, reflecting Leidos' competitive capabilities as an established federal contractor. The CDMRP, administered by the Defense Health Agency, funds peer-reviewed medical research across multiple disease areas, and this delivery order supports the kidney cancer research initiatives within that portfolio.
This delivery order represents a continuation of Leidos' extensive involvement in medical research support services across federal agencies. The company's parent, Leidos Holdings, Inc., has demonstrated significant capabilities in supporting research programs at agencies including the National Cancer Institute and Defense Health Agency. As a global technology and engineering solutions provider, Leidos leverages its technical and scientific expertise to manage administrative and programmatic functions that enable federally funded research efforts. The relatively modest contract value is consistent with typical delivery order sizes issued against larger indefinite delivery contracts, allowing the Defense Health Agency to procure specialized support services for its congressionally mandated cancer research mission.
Quick answers
Who was awarded contract HT942524F0064?
HT942524F0064 was awarded to Leidos, Inc. by Defense Health Agency (Department of Defense) on July 30, 2024.
How much is contract HT942524F0064 worth?
The government has obligated $256,417 on HT942524F0064. Its current value, with exercised options, is $364,347.
Is contract HT942524F0064 an order under another contract?
Yes. HT942524F0064 is a delivery order under HT942523D0002, an indefinite delivery contract.
Was contract HT942524F0064 competed?
The extent of competition for HT942524F0064 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award